Literature DB >> 10970095

Genomic organization and characterization of mouse SAP, the gene that is altered in X-linked lymphoproliferative disease.

C Wu1, J Sayos, N Wang, D Howie, A Coyle, C Terhorst.   

Abstract

X-linked lymphoproliferative (XLP) disease is a fatal immunological disorder that renders the immune system unable to respond effectively to Epstein-Barr virus (EBV) infection. The gene that encodes a protein termed SAP or SH2D1A is either deleted or mutated in XLP patients, resulting in uncontrolled B- and T-cell proliferation upon EBV infection. Here, we report the cloning and characterization of the mouse SAP gene. It is localized on the mouse X chromosome and comprises four exons spanning approximately 25 kb. Its expression appears to be restricted to T lymphocytes. Whereas a high level of SAP expression is observed in Thl cells, only small amounts are detectable in Th2 cells. Moreover, SAP expression is down-regulated upon in vitro activation of T cells, including CD4+, CD8+ single-positive T cells, and Thl and Th2 cells. This study provides valuable information for in-depth genetic and biochemical analysis of the function of SAP in the immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970095     DOI: 10.1007/s002510000215

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  11 in total

Review 1.  X-linked lymphoproliferative syndrome.

Authors:  D L Nelson; C Terhorst
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells.

Authors:  M Morra; J Lu; F Poy; M Martin; J Sayos; S Calpe; C Gullo; D Howie; S Rietdijk; A Thompson; A J Coyle; C Denny; M B Yaffe; P Engel; M J Eck; C Terhorst
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 3.  SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions.

Authors:  Cynthia Detre; Marton Keszei; Xavier Romero; George C Tsokos; Cox Terhorst
Journal:  Semin Immunopathol       Date:  2010-02-10       Impact factor: 9.623

4.  Differential methylation pattern of the X-linked lymphoproliferative (XLP) disease gene SH2D1A correlates with the cell lineage-specific transcription.

Authors:  Ornella Parolini; Andreas Weinhäusel; Birgit Kagerbauer; Joachim Sassmann; Wolfgang Holter; Helmut Gadner; Oskar A Haas; Walter Knapp
Journal:  Immunogenetics       Date:  2003-04-23       Impact factor: 2.846

5.  On immunologists and microbiologists: ground zero in the battle for interdisciplinary knowledge.

Authors:  Christine A Biron; Arturo Casadevall
Journal:  mBio       Date:  2010       Impact factor: 7.867

6.  Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia.

Authors:  Mike Recher; Ari J Fried; Michel J Massaad; Hye Young Kim; Michela Rizzini; Francesco Frugoni; Jolan E Walter; Divij Mathew; Hermann Eibel; Christoph Hess; Silvia Giliani; Dale T Umetsu; Luigi D Notarangelo; Raif S Geha
Journal:  Clin Immunol       Date:  2012-12-07       Impact factor: 3.969

7.  Slamf6 negatively regulates autoimmunity.

Authors:  Ninghai Wang; Marton Keszei; Peter Halibozek; Burcu Yigit; Pablo Engel; Cox Terhorst
Journal:  Clin Immunol       Date:  2016-06-29       Impact factor: 3.969

Review 8.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

Review 9.  Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Authors:  Masafumi Taniwaki; Mihoko Yoshida; Yosuke Matsumoto; Kazuho Shimura; Junya Kuroda; Hiroto Kaneko
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-02-15       Impact factor: 2.576

Review 10.  Responses to Microbial Challenges by SLAMF Receptors.

Authors:  Boaz Job van Driel; Gongxian Liao; Pablo Engel; Cox Terhorst
Journal:  Front Immunol       Date:  2016-01-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.